[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Page 9593]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-3177]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 10, 2008, Roche 
Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague 
Road, Indianapolis, Indiana 46250, made application by renewal to the 
Drug Enforcement Administration (DEA) as a bulk manufacturer of the 
basic classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (THC) (7370).........  I
Alphamethadol (9605).......................  I
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than April 21, 2008.

    Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-3177 Filed 2-20-08; 8:45 am]
BILLING CODE 4410-09-P